Tumor microenvironment-derived miRNAs as prognostic markers of breast cancer

Ny, Lukianova; Borikun, T V; Vf, Chekhun

doi:10.32471/exp-oncology.2312-8852.vol-41-no-3.13615

Cited by 13 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regulation by miRNAs has been strongly implicated in the progression of TNBC. Lymph node metastasis and a basal subtype was found to be associated with breast tumor expression of miR-155, miR-320a and miR-205 [13]. These associations extended to circulating miRNAs as well.…”

Section: Mirnas In Tnbc Tumorigenesis Promotion Progression and Stemnessmentioning

confidence: 79%

“…Since TNBC is a heterogeneous disease, multiple classification systems have been proposed [10][11][12]. Stromal factors and fibroblasts, immune suppression versus activation [10], tumor microenvironment (TME) classifications [13] and stem components [14] each contribute to tumor aggressiveness, prognosis, chemoresistance and targetability. Each of these components of the TME has unique molecular and genetic regulatory profiles that present different potential therapeutic targeting strategies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease

Qattan

2020

IJMS

View full text Add to dashboard Cite

Treatment of triple-negative breast cancer (TNBC) remains challenging because of the heterogeneity of the disease and lack of single targetable driving mutations. TNBC does not rely on estrogen, progesterone or epidermal growth factor receptors and is associated with aggressive disease progression and poor prognosis. TNBC is also characterized by resistance to chemotherapeutics, and response to immunotherapies is limited despite promising results in a subset of TNBC patients. MicroRNAs (miRNAs) have emerged as significant drivers of tumorigenesis and tumor progression in triple-negative breast cancer (TNBC) and present unique opportunities to target various components of the TNBC microenvironment for improved efficacy against this difficult to treat cancer. Effects of miRNAs on multiple targets may improve response rates in the context of this genetically and biologically heterogeneous disease. In this review, we offer a comprehensive view of miRNA regulation in TNBC, treatment challenges presented by TNBC in the context of the tumor microenvironment and stem cell subpopulations, and current and emerging miRNA-based therapeutic strategies targeting various components of the TNBC microenvironment. In addition, we offer insight into novel targets that have potential for treating TNBC through multiple mechanisms in the tumor microenvironment simultaneously and those that may be synergistic with standard chemotherapies.

show abstract

Section: Mirnas In Tnbc Tumorigenesis Promotion Progression and Stemnessmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease

Qattan

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In detail, Liu et al [27], Huang et al [29] and Lukianova et al [32] found that increased expression of serum miR-155 was significantly associated with LN metastases, whereas some other studies [26,30,31,35] reported no relationship between miR-155 expression and LN involvement. In single studies, circulating miR-155 was significantly associated with Ki-67 [26] and with TNBC [32]. Concerning the miR-155 association with tumour BC subtype, Lukiana et al found a significant correlation with TNBC subtypes, but opposing this were the results obtained by Anwar and colleagues [37].…”

Section: Circulating Mir-155 Versus Patient-and Tumour-related Prognomentioning

confidence: 99%

Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review

Grimaldi

Nuzzo

Condorelli

et al. 2020

IJMS

View full text Add to dashboard Cite

There is an unmet need for novel non-invasive prognostic molecular tumour markers for breast cancer (BC). Accumulating evidence shows that miR-155 plays a pivotal role in tumorigenesis. Generally, miR-155 is considered an oncogenic miRNA promoting tumour growth, angiogenesis and aggressiveness of BC. Therefore, many researchers have focused on its use as a prognostic biomarker and therapeutic target. However, its prognostic value for BC patients remains controversial. To address this issue, the present systematic review aims to summarize the available evidence and give a picture of a prognostic significance of miR-155 in BC pathology. All eligible studies were searched on PubMed and EMBASE databases through various search strategies. Starting from 289 potential eligible records, data were examined from 28 studies, comparing tissue and circulating miR-155 expression levels with clinicopathological features and survival rates in BC patients. We discuss the pitfalls and challenges that need to be assessed to understand the power of miR-155 to respond to real clinical needs, highlighting the consistency, robustness or lack of results obtained to sate in translating this molecule to clinical practice. Our paper suggests that the prognostic role of miR-155 in the management of BC needs to be further verified.

show abstract

“…Circulating expression of miR-155, miR-320a, and miR-205 correlated with lymph node metastases and basal breast cancer subtype. In conclusion, their report indicated that miR-155, miR-320a, and miR-205 could provide just some information on the major clinical-pathological features of BC, but not be used as a biomarker [ 109 ]. The prognostic significance of miR-34 rs4938723 T>C polymorphism has been investigated in TNBC by Andriani et al through IHC.…”

Section: Clinical Value Of Non-coding Rnas In Bcmentioning

confidence: 99%

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer

Sobhani

Chahwan

Roudi

et al. 2022

Cancers

View full text Add to dashboard Cite

For decades since the central dogma, cancer biology research has been focusing on the involvement of genes encoding proteins. It has been not until more recent times that a new molecular class has been discovered, named non-coding RNA (ncRNA), which has been shown to play crucial roles in shaping the activity of cells. An extraordinary number of studies has shown that ncRNAs represent an extensive and prevalent group of RNAs, including both oncogenic or tumor suppressive molecules. Henceforth, various clinical trials involving ncRNAs as extraordinary biomarkers or therapies have started to emerge. In this review, we will focus on the prognostic and diagnostic role of ncRNAs for breast cancer.

show abstract

Tumor microenvironment-derived miRNAs as prognostic markers of breast cancer

Cited by 13 publications

References 17 publications

Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease

Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease

Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer

Contact Info

Product

Resources

About